Advertisement Insight Agents launches generic contrast media solutions - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Insight Agents launches generic contrast media solutions

Insight Agents has reported the European launch of two new generic contrast media solutions for injection. Magnegita 500 micromol/ml is about to be introduced in 22 European countries and Iopamigita 300mg Iod/ml will be available for X-ray/CT in Germany.

At the same time, Insight Agents has presented a business model, which includes a range of services to radiologists. These include top purchase conditions from one of Europe’s largest group purchasing organizations in radiology. Instead of an expensive sales force, Insight Agents said that it provides value-added consulting services for hospital and private radiologists.

Johannes Schmidt-Tophoff, CEO of Insight Agents, said: “Our one-stop product range with surprisingly wide indication lists has a significant substitution potential in MRI and CT. As of today, our pro-active ingredients contribute to considerable cost savings in the health care sector. In addition, Insight Agents offers shares to radiologists and is committed to working hard for a potential benefit to radiology budgets and lobbying.”